{"drugResultsOutput": {"Filters": {"@total": "14", "Filter": [{"@total": "80", "@label": "Secondary Companies", "@name": "companiesSecondary", "FilterOption": [{"@id": "18630", "@count": "12", "@label": "State Research Center of Virology and Biotechnology VECTOR"}, {"@id": "14118", "@count": "3", "@label": "Lederle Laboratories"}, {"@id": "25584", "@count": "3", "@label": "Pfizer Vaccines"}, {"@id": "1009547", "@count": "2", "@label": "Sanofi"}, {"@id": "15385", "@count": "2", "@label": "Chiron Corp"}, {"@id": "21111", "@count": "2", "@label": "Mayo Foundation"}, {"@id": "22127", "@count": "2", "@label": "Sanofi Pasteur"}, {"@id": "21210", "@count": "2", "@label": "Medimmune Vaccines Inc"}, {"@id": "20623", "@count": "2", "@label": "University of Michigan"}, {"@id": "20691", "@count": "2", "@label": "Utah State University"}, {"@id": "20743", "@count": "2", "@label": "Vical Inc"}, {"@id": "19046", "@count": "2", "@label": "ViroPharma Inc"}, {"@id": "20059", "@count": "2", "@label": "SmithKline Beecham Pharma Inc"}, {"@id": "23137", "@count": "2", "@label": "Novartis AG"}, {"@id": "19962", "@count": "2", "@label": "SmithKline Beecham plc"}, {"@id": "19868", "@count": "1", "@label": "Shaman Pharmaceuticals Inc"}, {"@id": "14691", "@count": "1", "@label": "Shire BioChem Inc"}, {"@id": "22145", "@count": "1", "@label": "Sang-A Pharmaceutical Co Ltd"}, {"@id": "15496", "@count": "1", "@label": "Roemmers Laboratory"}, {"@id": "19446", "@count": "1", "@label": "Roche Holding AG"}, {"@id": "19365", "@count": "1", "@label": "Rhone-Poulenc Rorer Inc"}, {"@id": "20667", "@count": "1", "@label": "Ramot at Tel Aviv University Ltd"}, {"@id": "19181", "@count": "1", "@label": "Quadrant Technologies Ltd"}, {"@id": "19267", "@count": "1", "@label": "Pasteur Merieux Connaught Canada"}, {"@id": "20967", "@count": "1", "@label": "Yamanouchi Pharmaceutical Co Ltd"}, {"@id": "30739", "@count": "1", "@label": "Xanthus Pharmaceuticals Inc"}, {"@id": "14200", "@count": "1", "@label": "Wyeth-Ayerst Pharmaceuticals Inc"}, {"@id": "14112", "@count": "1", "@label": "Wyeth"}, {"@id": "20947", "@count": "1", "@label": "World Health Organization"}, {"@id": "20939", "@count": "1", "@label": "Whitehead Institute for Biomedical Research"}, {"@id": "14929", "@count": "1", "@label": "University of Tsukuba"}, {"@id": "25282", "@count": "1", "@label": "University of Catania"}, {"@id": "20524", "@count": "1", "@label": "University of Alabama at Birmingham"}, {"@id": "1064321", "@count": "1", "@label": "Universal Stabilization Technologies Inc"}, {"@id": "15336", "@count": "1", "@label": "UCB Celltech"}, {"@id": "21398", "@count": "1", "@label": "Trustees of Health & Hospitals of The City of Boston"}, {"@id": "20442", "@count": "1", "@label": "Trimeris Inc"}, {"@id": "20371", "@count": "1", "@label": "Therion Biologics Corp"}, {"@id": "25607", "@count": "1", "@label": "The Green Cross Corp"}, {"@id": "26483", "@count": "1", "@label": "Starpharma Holdings Ltd"}, {"@id": "24250", "@count": "1", "@label": "St Louis University"}, {"@id": "20226", "@count": "1", "@label": "Southern Research Institute"}, {"@id": "20567", "@count": "1", "@label": "Duke University"}, {"@id": "15563", "@count": "1", "@label": "CSL Ltd"}, {"@id": "24766", "@count": "1", "@label": "Crucell Switzerland AG"}, {"@id": "15505", "@count": "1", "@label": "Cistron Biotechnology Inc"}, {"@id": "25079", "@count": "1", "@label": "Chiron SpA"}, {"@id": "26857", "@count": "1", "@label": "Centers for Disease Control and Prevention"}, {"@id": "29469", "@count": "1", "@label": "Cancer Research UK"}, {"@id": "27013", "@count": "1", "@label": "Cambridge Drug Discovery Holdings plc"}, {"@id": "21028", "@count": "1", "@label": "Bulgarian Academy of Science"}, {"@id": "26864", "@count": "1", "@label": "Bristol-Myers Squibb Pharma Co"}, {"@id": "22585", "@count": "1", "@label": "Boehringer Ingelheim Corp (US)"}, {"@id": "14188", "@count": "1", "@label": "Biomolecular Research Institute Ltd"}, {"@id": "1051158", "@count": "1", "@label": "Biomolecular Pharma Inc"}, {"@id": "19693", "@count": "1", "@label": "Berlex Laboratories Inc"}, {"@id": "24244", "@count": "1", "@label": "Bavarian Nordic A/S"}, {"@id": "14239", "@count": "1", "@label": "Antisoma plc"}, {"@id": "26488", "@count": "1", "@label": "Agouron Pharmaceuticals Inc"}, {"@id": "24381", "@count": "1", "@label": "Adjuvantys Inc"}, {"@id": "18751", "@count": "1", "@label": "Acambis plc"}, {"@id": "22708", "@count": "1", "@label": "Oregon Health Sciences University"}, {"@id": "25528", "@count": "1", "@label": "Onyvax Ltd"}, {"@id": "1060505", "@count": "1", "@label": "Nisco International Inc"}, {"@id": "1032590", "@count": "1", "@label": "NAUKA"}, {"@id": "20518", "@count": "1", "@label": "National Institutes of Health"}, {"@id": "20983", "@count": "1", "@label": "Mitsubishi Pharma Corp"}, {"@id": "18077", "@count": "1", "@label": "Merck & Co Inc"}, {"@id": "17997", "@count": "1", "@label": "Medeva Inc"}, {"@id": "18225", "@count": "1", "@label": "Massachusetts Institute of Technology"}, {"@id": "20596", "@count": "1", "@label": "Johns Hopkins University"}, {"@id": "1002841", "@count": "1", "@label": "ImmuneRegen BioSciences Inc"}, {"@id": "25463", "@count": "1", "@label": "Hughes Institute"}, {"@id": "24108", "@count": "1", "@label": "Hedral Therapeutics Inc"}, {"@id": "1080922", "@count": "1", "@label": "Guangxi Beisheng Pharmaceutical Co Ltd"}, {"@id": "28355", "@count": "1", "@label": "GlaxoSmithKline plc"}, {"@id": "21948", "@count": "1", "@label": "GlaxoSmithKline Inc"}, {"@id": "24166", "@count": "1", "@label": "GlaxoSmithKline Biologicals"}, {"@id": "16453", "@count": "1", "@label": "Glaxo Group Ltd"}, {"@id": "16450", "@count": "1", "@label": "Gilead Sciences Inc"}]}, {"@total": "81", "@label": "Primary Companies", "@name": "companiesPrimary", "FilterOption": [{"@id": "28355", "@count": "10", "@label": "GlaxoSmithKline plc"}, {"@id": "18077", "@count": "5", "@label": "Merck & Co Inc"}, {"@id": "18630", "@count": "4", "@label": "State Research Center of Virology and Biotechnology VECTOR"}, {"@id": "19962", "@count": "4", "@label": "SmithKline Beecham plc"}, {"@id": "22127", "@count": "4", "@label": "Sanofi Pasteur"}, {"@id": "1052048", "@count": "3", "@label": "Sinovac (Dalian) Vaccine Technology Co Ltd"}, {"@id": "1071897", "@count": "3", "@label": "Shanghai Institute of Biological Products Co Ltd"}, {"@id": "1027662", "@count": "3", "@label": "Beijing Tiantan Biological Products Co Ltd"}, {"@id": "20573", "@count": "2", "@label": "Emory University"}, {"@id": "1069047", "@count": "2", "@label": "Emory University Technology Transfer Office"}, {"@id": "24166", "@count": "2", "@label": "GlaxoSmithKline Biologicals"}, {"@id": "17237", "@count": "2", "@label": "Institut Pasteur"}, {"@id": "1061250", "@count": "2", "@label": "Lanzhou Institute of Biological Products"}, {"@id": "1020606", "@count": "2", "@label": "Novartis Vaccines & Diagnostics"}, {"@id": "1009547", "@count": "2", "@label": "Sanofi"}, {"@id": "23408", "@count": "2", "@label": "Sanofi Pasteur MSD"}, {"@id": "20300", "@count": "2", "@label": "Takeda Pharmaceutical Co Ltd"}, {"@id": "1061252", "@count": "2", "@label": "Wuhan Institute of Biological Products Co Ltd"}, {"@id": "1016340", "@count": "2", "@label": "Chengdu Institute of Biological Products"}, {"@id": "24244", "@count": "2", "@label": "Bavarian Nordic A/S"}, {"@id": "15065", "@count": "2", "@label": "Bristol-Myers Squibb Co"}, {"@id": "1032149", "@count": "2", "@label": "Aktiv-Dry LLC"}, {"@id": "23137", "@count": "1", "@label": "Novartis AG"}, {"@id": "22584", "@count": "1", "@label": "Nippon Boehringer Ingelheim Co Ltd"}, {"@id": "1061492", "@count": "1", "@label": "Nuron Biotech Inc"}, {"@id": "23407", "@count": "1", "@label": "Pasteur Merieux"}, {"@id": "18767", "@count": "1", "@label": "Pfizer Inc"}, {"@id": "1007304", "@count": "1", "@label": "NeoTropiX Inc"}, {"@id": "1047333", "@count": "1", "@label": "PiKe Pharma GmbH"}, {"@id": "19446", "@count": "1", "@label": "Roche Holding AG"}, {"@id": "14881", "@count": "1", "@label": "Boehringer Ingelheim Corp"}, {"@id": "1049946", "@count": "1", "@label": "BioNet-Asia Co Ltd"}, {"@id": "30283", "@count": "1", "@label": "Sanofi Pasteur KK"}, {"@id": "30063", "@count": "1", "@label": "BIKEN"}, {"@id": "1018925", "@count": "1", "@label": "Sareum Holdings plc"}, {"@id": "1078819", "@count": "1", "@label": "Sevapharma Inc"}, {"@id": "1056577", "@count": "1", "@label": "Beijing Minhai Biotechnology Co Ltd"}, {"@id": "1054697", "@count": "1", "@label": "Shanxi Kangbao Biological Products Co Ltd"}, {"@id": "1041544", "@count": "1", "@label": "Shenzhen Weiwu Guangming Biological Products Co Ltd"}, {"@id": "1081842", "@count": "1", "@label": "Sichuan Yuanda Shuyang Pharmaceutical Co Ltd"}, {"@id": "24949", "@count": "1", "@label": "SIGA Technologies Inc"}, {"@id": "14455", "@count": "1", "@label": "Bayer AG"}, {"@id": "26914", "@count": "1", "@label": "SK Chemicals Co Ltd"}, {"@id": "1076477", "@count": "1", "@label": "Banghe Pharmaceutical Co Ltd"}, {"@id": "14190", "@count": "1", "@label": "AstraZeneca plc"}, {"@id": "20315", "@count": "1", "@label": "Tanabe Seiyaku Co Ltd"}, {"@id": "20442", "@count": "1", "@label": "Trimeris Inc"}, {"@id": "22301", "@count": "1", "@label": "Trinity Medical Group Co Ltd"}, {"@id": "1002892", "@count": "1", "@label": "VBI Vaccines"}, {"@id": "1050515", "@count": "1", "@label": "ViiV Healthcare"}, {"@id": "1075350", "@count": "1", "@label": "Dalian Aleph Biomedical Co Ltd"}, {"@id": "26816", "@count": "1", "@label": "Cytos Biotechnology Ltd"}, {"@id": "15563", "@count": "1", "@label": "CSL Ltd"}, {"@id": "26178", "@count": "1", "@label": "F Hoffmann-La Roche AG"}, {"@id": "16299", "@count": "1", "@label": "Genzyme Corp"}, {"@id": "16450", "@count": "1", "@label": "Gilead Sciences Inc"}, {"@id": "16453", "@count": "1", "@label": "Glaxo Group Ltd"}, {"@id": "27053", "@count": "1", "@label": "Glaxo Group Research Ltd"}, {"@id": "15387", "@count": "1", "@label": "Chiron Vaccines Co"}, {"@id": "15385", "@count": "1", "@label": "Chiron Corp"}, {"@id": "16583", "@count": "1", "@label": "Green Cross Corp"}, {"@id": "1079335", "@count": "1", "@label": "Guangdong Weilun Biological Products Co Ltd"}, {"@id": "1087965", "@count": "1", "@label": "Guizhou Taibang Biological Products Co Ltd"}, {"@id": "1072329", "@count": "1", "@label": "Harbin Pacific Biopharmaceutical Co Ltd"}, {"@id": "1077144", "@count": "1", "@label": "Hebei Da'an Pharmaceutical Co Ltd"}, {"@id": "1049660", "@count": "1", "@label": "Hualan Biological Engineering Inc"}, {"@id": "17199", "@count": "1", "@label": "Immune Response BioPharma Inc"}, {"@id": "17229", "@count": "1", "@label": "INSERM"}, {"@id": "1035636", "@count": "1", "@label": "INSERM Transfert"}, {"@id": "21072", "@count": "1", "@label": "Institute of Cancer Research UK"}, {"@id": "15374", "@count": "1", "@label": "Kaketsuken"}, {"@id": "29296", "@count": "1", "@label": "Koronis Pharmaceuticals Inc"}, {"@id": "30620", "@count": "1", "@label": "Cancer Research Technology Ltd"}, {"@id": "21111", "@count": "1", "@label": "Mayo Foundation"}, {"@id": "18008", "@count": "1", "@label": "MedImmune LLC"}, {"@id": "15134", "@count": "1", "@label": "Bristol-Myers Squibb KK"}, {"@id": "18090", "@count": "1", "@label": "Merck Sharp & Dohme Ltd"}, {"@id": "27949", "@count": "1", "@label": "MicroDose Therapeutx Inc"}, {"@id": "21991", "@count": "1", "@label": "Millennium Pharmaceuticals Inc"}, {"@id": "24019", "@count": "1", "@label": "MSD Japan"}, {"@id": "20519", "@count": "1", "@label": "National Cancer Institute"}]}, {"@total": "57", "@label": "Primary Indications", "@name": "indicationsPrimary", "FilterOption": [{"@id": "1", "@count": "35", "@label": "Measles virus infection"}, {"@id": "460", "@count": "15", "@label": "Rubella virus infection"}, {"@id": "449", "@count": "14", "@label": "Mumps virus infection"}, {"@id": "155", "@count": "12", "@label": "Hepatitis virus infection"}, {"@id": "145", "@count": "7", "@label": "Haemophilus influenzae infection"}, {"@id": "159", "@count": "4", "@label": "HIV-1 infection"}, {"@id": "152", "@count": "4", "@label": "Hepatitis B virus infection"}, {"@id": "81", "@count": "4", "@label": "Corynebacterium diphtheriae infection"}, {"@id": "72", "@count": "4", "@label": "Clostridium tetani infection"}, {"@id": "344", "@count": "4", "@label": "Viral infection"}, {"@id": "392", "@count": "4", "@label": "Varicella zoster virus infection"}, {"@id": "389", "@count": "4", "@label": "Neisseria meningitidis infection"}, {"@id": "47", "@count": "4", "@label": "Bordetella pertussis infection"}, {"@id": "1283", "@count": "3", "@label": "Japanese encephalitis virus infection"}, {"@id": "158", "@count": "3", "@label": "HIV infection"}, {"@id": "1811", "@count": "2", "@label": "Neisseria meningitidis meningitis"}, {"@id": "1803", "@count": "2", "@label": "Bacterial meningitis"}, {"@id": "40", "@count": "2", "@label": "Bacterial infection"}, {"@id": "1128", "@count": "2", "@label": "Neuroendocrine tumor"}, {"@id": "1261", "@count": "2", "@label": "Small-cell lung cancer"}, {"@id": "1744", "@count": "2", "@label": "Mantle cell lymphoma"}, {"@id": "191", "@count": "2", "@label": "Influenza virus infection"}, {"@id": "651", "@count": "2", "@label": "Cancer"}, {"@id": "799", "@count": "2", "@label": "Ovary tumor"}, {"@id": "319", "@count": "2", "@label": "Non-Hodgkin lymphoma"}, {"@id": "287", "@count": "2", "@label": "Respiratory syncytial virus infection"}, {"@id": "153", "@count": "2", "@label": "Hepatitis C virus infection"}, {"@id": "1270", "@count": "2", "@label": "Variola virus infection"}, {"@id": "1262", "@count": "1", "@label": "Non-small-cell lung cancer"}, {"@id": "695", "@count": "1", "@label": "Paramyxovirus infection"}, {"@id": "1777", "@count": "1", "@label": "Pediatric varicella zoster virus infection"}, {"@id": "1753", "@count": "1", "@label": "Peripheral T-cell lymphoma"}, {"@id": "3083", "@count": "1", "@label": "Peritoneal tumor"}, {"@id": "267", "@count": "1", "@label": "Plasmodium falciparum infection"}, {"@id": "272", "@count": "1", "@label": "Poliovirus infection"}, {"@id": "725", "@count": "1", "@label": "Solid tumor"}, {"@id": "347", "@count": "1", "@label": "Wound healing"}, {"@id": "1731", "@count": "1", "@label": "Acute myelogenous leukemia"}, {"@id": "1776", "@count": "1", "@label": "Adult varicella zoster virus infection"}, {"@id": "14", "@count": "1", "@label": "Alzheimers disease"}, {"@id": "31", "@count": "1", "@label": "Asthma"}, {"@id": "33", "@count": "1", "@label": "Atherosclerosis"}, {"@id": "316", "@count": "1", "@label": "B-cell lymphoma"}, {"@id": "49", "@count": "1", "@label": "Breast tumor"}, {"@id": "791", "@count": "1", "@label": "Burkitts lymphoma"}, {"@id": "1734", "@count": "1", "@label": "Chronic lymphocytic leukemia"}, {"@id": "2458", "@count": "1", "@label": "Dengue virus infection"}, {"@id": "1749", "@count": "1", "@label": "Diffuse large B-cell lymphoma"}, {"@id": "1011", "@count": "1", "@label": "Esophagus tumor"}, {"@id": "1745", "@count": "1", "@label": "Follicle center lymphoma"}, {"@id": "2454", "@count": "1", "@label": "Glioblastoma"}, {"@id": "623", "@count": "1", "@label": "Head and neck tumor"}, {"@id": "151", "@count": "1", "@label": "Hepatitis A virus infection"}, {"@id": "3246", "@count": "1", "@label": "Hormone refractory prostate cancer"}, {"@id": "1240", "@count": "1", "@label": "Mesothelioma"}, {"@id": "3665", "@count": "1", "@label": "Metastatic non small cell lung cancer"}, {"@id": "1828", "@count": "1", "@label": "Multiple myeloma"}]}, {"@total": "54", "@label": "Secondary Indications", "@name": "indicationsSecondary", "FilterOption": [{"@id": "1", "@count": "14", "@label": "Measles virus infection"}, {"@id": "651", "@count": "12", "@label": "Cancer"}, {"@id": "344", "@count": "5", "@label": "Viral infection"}, {"@id": "145", "@count": "4", "@label": "Haemophilus influenzae infection"}, {"@id": "47", "@count": "4", "@label": "Bordetella pertussis infection"}, {"@id": "152", "@count": "3", "@label": "Hepatitis B virus infection"}, {"@id": "746", "@count": "3", "@label": "Infectious disease"}, {"@id": "72", "@count": "3", "@label": "Clostridium tetani infection"}, {"@id": "81", "@count": "3", "@label": "Corynebacterium diphtheriae infection"}, {"@id": "191", "@count": "3", "@label": "Influenza virus infection"}, {"@id": "287", "@count": "3", "@label": "Respiratory syncytial virus infection"}, {"@id": "158", "@count": "2", "@label": "HIV infection"}, {"@id": "623", "@count": "2", "@label": "Head and neck tumor"}, {"@id": "40", "@count": "2", "@label": "Bacterial infection"}, {"@id": "231", "@count": "1", "@label": "Nephritis"}, {"@id": "230", "@count": "1", "@label": "Neoplasm"}, {"@id": "799", "@count": "1", "@label": "Ovary tumor"}, {"@id": "1811", "@count": "1", "@label": "Neisseria meningitidis meningitis"}, {"@id": "1272", "@count": "1", "@label": "Myelodysplastic syndrome"}, {"@id": "396", "@count": "1", "@label": "Papillomavirus infection"}, {"@id": "221", "@count": "1", "@label": "Mycobacterium tuberculosis infection"}, {"@id": "451", "@count": "1", "@label": "Parainfluenza virus infection"}, {"@id": "264", "@count": "1", "@label": "Picornavirus infection"}, {"@id": "474", "@count": "1", "@label": "Poison intoxication"}, {"@id": "281", "@count": "1", "@label": "Psoriasis"}, {"@id": "69", "@count": "1", "@label": "Renal failure"}, {"@id": "711", "@count": "1", "@label": "Respiratory disease"}, {"@id": "460", "@count": "1", "@label": "Rubella virus infection"}, {"@id": "65", "@count": "1", "@label": "Stroke"}, {"@id": "1005", "@count": "1", "@label": "Unidentified indication"}, {"@id": "384", "@count": "1", "@label": "Vaccination"}, {"@id": "1818", "@count": "1", "@label": "Viral pneumonia"}, {"@id": "347", "@count": "1", "@label": "Wound healing"}, {"@id": "1731", "@count": "1", "@label": "Acute myelogenous leukemia"}, {"@id": "13", "@count": "1", "@label": "Alopecia"}, {"@id": "31", "@count": "1", "@label": "Asthma"}, {"@id": "36", "@count": "1", "@label": "Autoimmune disease"}, {"@id": "49", "@count": "1", "@label": "Breast tumor"}, {"@id": "989", "@count": "1", "@label": "Colorectal tumor"}, {"@id": "89", "@count": "1", "@label": "Cytomegalovirus infection"}, {"@id": "1049", "@count": "1", "@label": "Ebola virus infection"}, {"@id": "122", "@count": "1", "@label": "Flavivirus infection"}, {"@id": "2454", "@count": "1", "@label": "Glioblastoma"}, {"@id": "1108", "@count": "1", "@label": "Glioma"}, {"@id": "155", "@count": "1", "@label": "Hepatitis virus infection"}, {"@id": "157", "@count": "1", "@label": "Herpes simplex virus infection"}, {"@id": "1124", "@count": "1", "@label": "Herpesvirus infection"}, {"@id": "3771", "@count": "1", "@label": "Idiopathic pulmonary fibrosis"}, {"@id": "504", "@count": "1", "@label": "Immune deficiency"}, {"@id": "755", "@count": "1", "@label": "Lung tumor"}, {"@id": "205", "@count": "1", "@label": "Melanoma"}, {"@id": "1828", "@count": "1", "@label": "Multiple myeloma"}, {"@id": "213", "@count": "1", "@label": "Multiple sclerosis"}, {"@id": "449", "@count": "1", "@label": "Mumps virus infection"}]}, {"@total": "52", "@label": "Technologies", "@name": "technologies", "FilterOption": [{"@id": "761", "@count": "97", "@label": "Biological therapeutic"}, {"@id": "762", "@count": "37", "@label": "Small molecule therapeutic"}, {"@id": "766", "@count": "30", "@label": "Parenteral formulation unspecified"}, {"@id": "651", "@count": "28", "@label": "Intramuscular formulation"}, {"@id": "647", "@count": "16", "@label": "Subcutaneous formulation"}, {"@id": "582", "@count": "13", "@label": "Antibody polyclonal"}, {"@id": "1651", "@count": "13", "@label": "Blood constituents"}, {"@id": "4", "@count": "13", "@label": "Immunoglobulin"}, {"@id": "62", "@count": "11", "@label": "Virus recombinant"}, {"@id": "746", "@count": "9", "@label": "Solution"}, {"@id": "80", "@count": "9", "@label": "Peptide"}, {"@id": "596", "@count": "9", "@label": "Injectable formulation"}, {"@id": "585", "@count": "8", "@label": "Oral formulation"}, {"@id": "159", "@count": "6", "@label": "Oligosaccharide"}, {"@id": "616", "@count": "6", "@label": "Inhalant formulation"}, {"@id": "595", "@count": "5", "@label": "Tablet formulation"}, {"@id": "207", "@count": "3", "@label": "Protein conjugated"}, {"@id": "586", "@count": "3", "@label": "Capsule formulation"}, {"@id": "603", "@count": "3", "@label": "Systemic formulation unspecified"}, {"@id": "175", "@count": "3", "@label": "Drug combination"}, {"@id": "605", "@count": "3", "@label": "Nasal systemic formulation"}, {"@id": "648", "@count": "3", "@label": "Intravenous formulation"}, {"@id": "617", "@count": "3", "@label": "Aerosol formulation inhalant"}, {"@id": "750", "@count": "3", "@label": "Freeze drying"}, {"@id": "85", "@count": "2", "@label": "Protein recombinant"}, {"@id": "84", "@count": "2", "@label": "Protein fusion"}, {"@id": "618", "@count": "2", "@label": "Powder formulation inhalant"}, {"@id": "611", "@count": "2", "@label": "Dermatological formulation"}, {"@id": "740", "@count": "2", "@label": "Infusion"}, {"@id": "751", "@count": "2", "@label": "Film coating"}, {"@id": "851", "@count": "2", "@label": "Intradermal formulation"}, {"@id": "92", "@count": "2", "@label": "Viral coat protein"}, {"@id": "589", "@count": "1", "@label": "Sustained release formulation"}, {"@id": "745", "@count": "1", "@label": "Suspension"}, {"@id": "67", "@count": "1", "@label": "Antigen"}, {"@id": "630", "@count": "1", "@label": "Stereochemistry"}, {"@id": "232", "@count": "1", "@label": "Virus novel"}, {"@id": "127", "@count": "1", "@label": "Cell culture"}, {"@id": "558", "@count": "1", "@label": "Transdermal formulation"}, {"@id": "117", "@count": "1", "@label": "RNA technology"}, {"@id": "1652", "@count": "1", "@label": "Prodrug"}, {"@id": "667", "@count": "1", "@label": "Peptidomimetic"}, {"@id": "641", "@count": "1", "@label": "Controlled release formulation"}, {"@id": "600", "@count": "1", "@label": "Patch formulation"}, {"@id": "660", "@count": "1", "@label": "Oral sustained release formulation"}, {"@id": "594", "@count": "1", "@label": "Oral suspension formulation"}, {"@id": "112", "@count": "1", "@label": "DNA technology"}, {"@id": "103", "@count": "1", "@label": "Oligonucleotide"}, {"@id": "347", "@count": "1", "@label": "Intratumoral formulation"}, {"@id": "590", "@count": "1", "@label": "Enteric coated formulation"}, {"@id": "898", "@count": "1", "@label": "Formulation powder"}, {"@id": "74", "@count": "1", "@label": "Glycoprotein"}]}, {"@total": "48", "@label": "Secondary Actions", "@name": "actionsSecondary", "FilterOption": [{"@id": "12378", "@count": "63", "@label": "Prophylactic vaccine"}, {"@id": "991", "@count": "35", "@label": "Antiviral"}, {"@id": "59620", "@count": "34", "@label": "Unspecified drug target"}, {"@id": "12364", "@count": "32", "@label": "Live attenuated viral vaccine"}, {"@id": "1545", "@count": "17", "@label": "Anticancer"}, {"@id": "393", "@count": "11", "@label": "Immunostimulant"}, {"@id": "12375", "@count": "9", "@label": "Toxoid vaccine"}, {"@id": "2953", "@count": "8", "@label": "Anti-inflammatory"}, {"@id": "1532", "@count": "8", "@label": "Viral replication inhibitor"}, {"@id": "12379", "@count": "8", "@label": "Therapeutic vaccine"}, {"@id": "12370", "@count": "7", "@label": "Recombinant viral vector vaccine"}, {"@id": "12371", "@count": "6", "@label": "Subunit vaccine"}, {"@id": "12373", "@count": "6", "@label": "Polysaccharide subunit vaccine"}, {"@id": "12372", "@count": "4", "@label": "Protein subunit vaccine"}, {"@id": "1596", "@count": "4", "@label": "Immunomodulator"}, {"@id": "1594", "@count": "4", "@label": "Antibacterial"}, {"@id": "62255", "@count": "2", "@label": "Anticancer protein kinase inhibitor"}, {"@id": "1833", "@count": "2", "@label": "Non-nucleoside reverse transcriptase inhibitor"}, {"@id": "1615", "@count": "2", "@label": "Neuroprotectant"}, {"@id": "1589", "@count": "2", "@label": "Apoptosis stimulator"}, {"@id": "12367", "@count": "2", "@label": "Inactivated viral vaccine"}, {"@id": "913", "@count": "2", "@label": "TNF modulator"}, {"@id": "1879", "@count": "2", "@label": "DNA vaccine"}, {"@id": "3980", "@count": "2", "@label": "HIV fusion inhibitor"}, {"@id": "386", "@count": "1", "@label": "Vaccine"}, {"@id": "7760", "@count": "1", "@label": "T-lymphocyte inhibitor"}, {"@id": "12380", "@count": "1", "@label": "Unspecified vaccine"}, {"@id": "15184", "@count": "1", "@label": "Systemic antipsoriatic product"}, {"@id": "2836", "@count": "1", "@label": "Viral enzyme inhibitor"}, {"@id": "7293", "@count": "1", "@label": "Synergist"}, {"@id": "2837", "@count": "1", "@label": "Viral protease inhibitor"}, {"@id": "1720", "@count": "1", "@label": "Virus uptake inhibitor"}, {"@id": "1542", "@count": "1", "@label": "Radiosensitizer"}, {"@id": "1465", "@count": "1", "@label": "Radioprotectant"}, {"@id": "339", "@count": "1", "@label": "Protein synthesis inhibitor"}, {"@id": "959", "@count": "1", "@label": "Protectant"}, {"@id": "1832", "@count": "1", "@label": "Nucleoside reverse transcriptase inhibitor"}, {"@id": "12363", "@count": "1", "@label": "Live attenuated bacterial vaccine"}, {"@id": "1379", "@count": "1", "@label": "Interferon modulator"}, {"@id": "396", "@count": "1", "@label": "Immunosuppressant"}, {"@id": "747", "@count": "1", "@label": "HIV replication inhibitor"}, {"@id": "664", "@count": "1", "@label": "Fibrosuppressant"}, {"@id": "140", "@count": "1", "@label": "DNA synthesis inhibitor"}, {"@id": "1276", "@count": "1", "@label": "Chemoprotectant"}, {"@id": "62253", "@count": "1", "@label": "Anticancer hormone"}, {"@id": "1569", "@count": "1", "@label": "Anticancer antimetabolite"}, {"@id": "2667", "@count": "1", "@label": "Antiarteriosclerotic"}, {"@id": "524", "@count": "1", "@label": "Adjuvant"}]}, {"@total": "82", "@label": "Drug Added by Day", "@name": "drugAddedDateByDay", "FilterOption": [{"@count": "33", "@label": "1996-02-16"}, {"@count": "13", "@label": "1996-07-02"}, {"@count": "3", "@label": "2012-08-16"}, {"@count": "2", "@label": "2012-08-20"}, {"@count": "2", "@label": "2012-07-09"}, {"@count": "2", "@label": "2006-05-10"}, {"@count": "2", "@label": "2013-04-29"}, {"@count": "2", "@label": "1998-05-08"}, {"@count": "1", "@label": "2008-07-29"}, {"@count": "1", "@label": "2012-07-10"}, {"@count": "1", "@label": "2012-07-07"}, {"@count": "1", "@label": "2012-04-27"}, {"@count": "1", "@label": "2012-02-15"}, {"@count": "1", "@label": "2012-01-10"}, {"@count": "1", "@label": "2011-08-18"}, {"@count": "1", "@label": "2011-08-01"}, {"@count": "1", "@label": "2011-04-21"}, {"@count": "1", "@label": "2011-03-22"}, {"@count": "1", "@label": "2011-03-11"}, {"@count": "1", "@label": "2011-01-11"}, {"@count": "1", "@label": "2010-05-24"}, {"@count": "1", "@label": "2010-04-07"}, {"@count": "1", "@label": "2010-01-28"}, {"@count": "1", "@label": "2009-08-21"}, {"@count": "1", "@label": "2014-01-16"}, {"@count": "1", "@label": "2014-01-08"}, {"@count": "1", "@label": "2013-09-20"}, {"@count": "1", "@label": "2013-09-04"}, {"@count": "1", "@label": "2013-07-10"}, {"@count": "1", "@label": "2013-07-05"}, {"@count": "1", "@label": "2013-06-14"}, {"@count": "1", "@label": "2013-05-23"}, {"@count": "1", "@label": "2013-04-22"}, {"@count": "1", "@label": "2013-03-11"}, {"@count": "1", "@label": "2013-03-01"}, {"@count": "1", "@label": "2013-01-14"}, {"@count": "1", "@label": "2012-11-27"}, {"@count": "1", "@label": "2012-11-02"}, {"@count": "1", "@label": "2012-10-01"}, {"@count": "1", "@label": "2012-08-30"}, {"@count": "1", "@label": "2012-08-22"}, {"@count": "1", "@label": "2012-08-21"}, {"@count": "1", "@label": "2012-08-03"}, {"@count": "1", "@label": "2002-03-21"}, {"@count": "1", "@label": "2002-01-02"}, {"@count": "1", "@label": "2001-05-22"}, {"@count": "1", "@label": "2001-02-22"}, {"@count": "1", "@label": "2000-08-17"}, {"@count": "1", "@label": "2000-06-19"}, {"@count": "1", "@label": "1999-04-26"}, {"@count": "1", "@label": "1999-02-22"}, {"@count": "1", "@label": "1998-10-15"}, {"@count": "1", "@label": "1998-08-28"}, {"@count": "1", "@label": "1998-02-04"}, {"@count": "1", "@label": "1997-12-11"}, {"@count": "1", "@label": "1997-06-05"}, {"@count": "1", "@label": "1997-04-15"}, {"@count": "1", "@label": "1997-01-09"}, {"@count": "1", "@label": "1996-10-28"}, {"@count": "1", "@label": "1996-08-30"}, {"@count": "1", "@label": "1996-06-11"}, {"@count": "1", "@label": "1996-04-18"}, {"@count": "1", "@label": "2008-07-09"}, {"@count": "1", "@label": "2007-10-03"}, {"@count": "1", "@label": "2007-06-04"}, {"@count": "1", "@label": "2007-06-01"}, {"@count": "1", "@label": "2007-05-01"}, {"@count": "1", "@label": "2006-09-20"}, {"@count": "1", "@label": "2006-05-26"}, {"@count": "1", "@label": "2006-02-15"}, {"@count": "1", "@label": "2005-11-29"}, {"@count": "1", "@label": "2005-10-27"}, {"@count": "1", "@label": "2004-12-14"}, {"@count": "1", "@label": "2004-03-23"}, {"@count": "1", "@label": "2004-01-16"}, {"@count": "1", "@label": "2003-10-28"}, {"@count": "1", "@label": "2003-10-21"}, {"@count": "1", "@label": "2003-08-14"}, {"@count": "1", "@label": "2003-07-30"}, {"@count": "1", "@label": "2002-10-14"}, {"@count": "1", "@label": "2002-08-12"}, {"@count": "1", "@label": "2002-04-03"}]}, {"@total": "24", "@label": "Primary Actions", "@name": "actionsPrimary", "FilterOption": [{"@id": "347", "@count": "2", "@label": "RNA polymerase inhibitor"}, {"@id": "5281", "@count": "2", "@label": "CD66e modulator"}, {"@id": "1053", "@count": "1", "@label": "Unspecified enzyme inhibitor"}, {"@id": "551", "@count": "1", "@label": "RNA DNA polymerase inhibitor"}, {"@id": "346", "@count": "1", "@label": "Ribonucleotide reductase inhibitor"}, {"@id": "345", "@count": "1", "@label": "Reverse transcriptase inhibitor"}, {"@id": "10451", "@count": "1", "@label": "Ras GTPase inhibitor"}, {"@id": "281", "@count": "1", "@label": "NMDA receptor antagonist"}, {"@id": "565", "@count": "1", "@label": "NK1 receptor agonist"}, {"@id": "48507", "@count": "1", "@label": "Major envelope protein p37 inhibitor"}, {"@id": "12481", "@count": "1", "@label": "Interleukin-2 ligand"}, {"@id": "12478", "@count": "1", "@label": "Interleukin-1 beta ligand"}, {"@id": "214", "@count": "1", "@label": "Interferon alpha 2 ligand"}, {"@id": "11466", "@count": "1", "@label": "HIV gp41 protein modulator"}, {"@id": "410", "@count": "1", "@label": "GM-CSF receptor agonist"}, {"@id": "2501", "@count": "1", "@label": "Erythropoietin receptor agonist"}, {"@id": "3755", "@count": "1", "@label": "Erbb2 tyrosine kinase receptor modulator"}, {"@id": "6830", "@count": "1", "@label": "DNA primase inhibitor"}, {"@id": "138", "@count": "1", "@label": "DNA polymerase inhibitor"}, {"@id": "51708", "@count": "1", "@label": "DNA polymerase alpha inhibitor"}, {"@id": "4438", "@count": "1", "@label": "Checkpoint kinase 1 inhibitor"}, {"@id": "5325", "@count": "1", "@label": "CD80 modulator"}, {"@id": "2420", "@count": "1", "@label": "Beta amyloid modulator"}, {"@id": "4420", "@count": "1", "@label": "Aurora protein kinase 2 inhibitor"}]}, {"@total": "14", "@label": "Drug Deal Types", "@name": "drugDealTypes", "FilterOption": [{"@id": "4", "@count": "23", "@label": "Drug - Development/Commercialization License"}, {"@id": "13", "@count": "12", "@label": "Drug - Funding"}, {"@id": "10", "@count": "9", "@label": "Technology - Other Proprietary"}, {"@id": "5", "@count": "7", "@label": "Drug - Commercialization License"}, {"@id": "6", "@count": "6", "@label": "Drug - Manufacturing/Supply"}, {"@id": "15", "@count": "5", "@label": "Drug - CRADA"}, {"@id": "7", "@count": "5", "@label": "Drug - Development Services"}, {"@id": "8", "@count": "5", "@label": "Technology - Delivery/Formulation"}, {"@id": "14", "@count": "4", "@label": "Drug - Asset Divestment"}, {"@id": "3", "@count": "4", "@label": "Drug - Early Research/Development"}, {"@id": "11", "@count": "4", "@label": "Patent - Exclusive Rights"}, {"@id": "2", "@count": "1", "@label": "Drug - Screening/Evaluation"}, {"@id": "12", "@count": "1", "@label": "Patent - Non-Exclusive Rights"}, {"@id": "9", "@count": "1", "@label": "Technology - Target Validation"}]}, {"@total": "10", "@label": "Highest Phase", "@name": "phaseHighest", "FilterOption": [{"@id": "L", "@count": "53", "@label": "Launched"}, {"@id": "NDR", "@count": "36", "@label": "No Development Reported"}, {"@id": "DR", "@count": "16", "@label": "Discovery"}, {"@id": "DX", "@count": "11", "@label": "Discontinued"}, {"@id": "C1", "@count": "4", "@label": "Phase 1 Clinical"}, {"@id": "C3", "@count": "4", "@label": "Phase 3 Clinical"}, {"@id": "C2", "@count": "3", "@label": "Phase 2 Clinical"}, {"@id": "R", "@count": "3", "@label": "Registered"}, {"@id": "W", "@count": "2", "@label": "Withdrawn"}, {"@id": "PR", "@count": "1", "@label": "Pre-registration"}]}, {"@total": "5", "@label": "Drug Sales 2010 (USD M)", "@name": "drugSalesYearActual", "FilterOption": [{"@count": "4", "@label": "< 100"}, {"@count": "1", "@label": "\u2265 100 and  250"}, {"@count": "2", "@label": "\u2265 250 and  500"}, {"@count": "2", "@label": "\u2265 500 and  1000"}, {"@count": "1", "@label": "\u2265 1000"}]}, {"@total": "8", "@label": "Drug Deals Count", "@name": "drugDealsCount", "FilterOption": [{"@count": "90", "@label": "= 0"}, {"@count": "16", "@label": "> 1 and \u2264 1"}, {"@count": "12", "@label": "> 2 and \u2264 2"}, {"@count": "3", "@label": "> 3 and \u2264 3"}, {"@count": "6", "@label": "> 4 and \u2264 4"}, {"@count": "2", "@label": "> 5 and \u2264 5"}, {"@count": "3", "@label": "> 6 and \u2264 10"}, {"@count": "1", "@label": "> 11"}]}, {"@total": "2", "@label": "Drug Has Financials", "@name": "drugHasFinancials", "FilterOption": [{"@count": "118", "@label": "No"}, {"@count": "15", "@label": "Yes"}]}]}, "SearchResults": {"Drug": [{"CompanyOriginator": "Emory University", "AddedDate": "2012-04-27T00:00:00Z", "@name": "non-nucleoside RDRP inhibitors (measles virus infection), Emory University", "ActionsPrimary": {"Action": "RNA polymerase inhibitor"}, "Summary": "...dependent RNA polymerase (RDRP) inhibitors, for the potential treatment of <b>measles</b> <b>virus</b> <b>infection</b> [1283279], [1276737], [1276728]. In February 2012, the program was listed as...1276737].By April 2007, the most potent compound had acted as a target-specific <b>measles</b> virus replication inhibitor, and had desirable drug-like properties. The compound was highly active against multiple primary isolates of diverse <b>measles</b> virus genotypes. Mechanistic characterization on a subinfection level showed...", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": ["Emory University", "Emory University Technology Transfer Office"]}, "Technologies": {"Technology": "Small molecule therapeutic"}, "IndicationsPrimary": {"Indication": "Measles virus infection"}, "@id": "77538", "@lastModificationDate": "2012-04-27T00:00:00Z", "ActionsSecondary": {"Action": "Viral replication inhibitor"}}, {"CompanyOriginator": "Biomolecular Pharma Inc", "AddedDate": "2010-01-28T00:00:00Z", "@name": "ESP (multiple sclerosis/measles virus infection), Biomolecular Pharma", "Summary": "As no development has been reported for some time, this program is assumed to be discontinued.Biomolecular Pharma was developing ESP, an analog of the active metabolite of azathioprine, for the potential treatment of <b>measles</b> <b>virus</b> <b>infection</b>, believed by the company to be the cause of multiple sclerosis [1071082], [1218244]. By January 2010, a pilot study had been conducted [1071082]; in August 2011, development was ongoing [1218235].By January 2010, a pilot study had been conducted with seven...", "IndicationsSecondary": {"Indication": ["Measles virus infection", "Multiple sclerosis"]}, "@phaseHighest": "No Development Reported", "ActionsSecondary": {"Action": ["Antiviral", "Unspecified drug target"]}, "Technologies": {"Technology": ["Small molecule therapeutic", "Systemic formulation unspecified"]}, "CompaniesSecondary": {"Company": "Biomolecular Pharma Inc"}, "@id": "65451", "@lastModificationDate": "2013-02-01T00:00:00Z"}, {"CompanyOriginator": "Sinovac (Dalian) Vaccine Technology Co Ltd", "AddedDate": "2012-08-16T00:00:00Z", "@name": "measles vaccine, Sinovac Dalian", "Summary": "Sinovac Dalian is investigating live attenuated vaccine for the potential prevention of <b>measles</b> <b>virus</b> <b>infection</b>. In May 2011, development was ongoing [1201231].In May 2010, Sinovac Dalian planned to commercialise a combination <b>measles</b>, mumps and rubella vaccine MMR that would be eligible for a government purchasing program, following approval of the mumps vaccine [1096130].", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "Sinovac (Dalian) Vaccine Technology Co Ltd"}, "Technologies": {"Technology": ["Biological therapeutic", "Parenteral formulation unspecified"]}, "IndicationsPrimary": {"Indication": "Measles virus infection"}, "@id": "80163", "@lastModificationDate": "2012-08-16T00:00:00Z", "ActionsSecondary": {"Action": ["Live attenuated viral vaccine", "Prophylactic vaccine"]}}, {"CompanyOriginator": "Aktiv-Dry LLC", "AddedDate": "2007-05-01T00:00:00Z", "@name": "measles vaccine (inhaled dry powder/CAN-BD), Aktiv-Dry", "Summary": "...Nebulization with a Bubble Dryer (CAN-BD) technology, for the potential prevention of <b>measles</b> <b>virus</b> <b>infection</b> [789191], [789238], [1262652]. In March 2012, a phase I trial began. In September...CHI's Eighth Annual PepTalk Conference in San Diego, CA. Using the Edmonston-Zagreb <b>measles</b> strain, the immune response elicited in an animal model when the vaccine was stabilized...2005, the company was awarded $19.5 million by the NIH to support development of the <b>measles</b> vaccine [789191].", "@phaseHighest": "Phase 1 Clinical", "CompaniesPrimary": {"Company": "Aktiv-Dry LLC"}, "Technologies": {"Technology": ["Biological therapeutic", "Inhalant formulation", "Powder formulation inhalant"]}, "IndicationsPrimary": {"Indication": "Measles virus infection"}, "@id": "57263", "@lastModificationDate": "2013-05-16T00:00:00Z", "ActionsSecondary": {"Action": ["Live attenuated viral vaccine", "Prophylactic vaccine"]}}, {"CompanyOriginator": "State Research Center of Virology and Biotechnology VECTOR", "AddedDate": "1996-07-02T00:00:00Z", "@name": "measles vaccine, NPO Vector", "Summary": "NPO Vector's (now SRC VB Vector) vaccine to prevent <b>measles</b> <b>virus</b> <b>infection</b> had been launched in Russia as of 2000 [359687], [360889]; it was awaiting registration in Russia in May 1996 [212606].", "@phaseHighest": "Launched", "CompaniesPrimary": {"Company": "State Research Center of Virology and Biotechnology VECTOR"}, "Technologies": {"Technology": ["Biological therapeutic", "Parenteral formulation unspecified"]}, "IndicationsPrimary": {"Indication": "Measles virus infection"}, "@id": "12671", "@lastModificationDate": "2006-02-27T00:00:00Z", "ActionsSecondary": {"Action": "Prophylactic vaccine"}}, {"CompanyOriginator": "Sanofi Pasteur", "AddedDate": "2014-01-16T00:00:00Z", "@name": "M-M-RvaxPRO", "Summary": "Sanofi Pasteur has developed and launched a triple live-attenuated vaccine (M-M-RvaxPRO) for <b>measles</b>, mumps and rubella. The vaccine is indicated for simultaneous vaccination against <b>measles</b>, mumps, and rubella in individuals from 12 months of age and in indivduals between 9 and 12 months of age under special circumstances [1515675]. In May 2006, M-M-RvaxPRO was approved in the EU and presumed the be launched shortly afterwards [1515679].In June 2004, Sanofi Pasteur filed an MAA with the EMA through...", "@phaseHighest": "Launched", "CompaniesPrimary": {"Company": "Sanofi Pasteur"}, "Technologies": {"Technology": ["Biological therapeutic", "Intramuscular formulation", "Subcutaneous formulation"]}, "IndicationsPrimary": {"Indication": ["Measles virus infection", "Mumps virus infection", "Rubella virus infection"]}, "@id": "89684", "@lastModificationDate": "2014-01-16T00:00:00Z", "ActionsSecondary": {"Action": ["Live attenuated viral vaccine", "Prophylactic vaccine"]}}, {"CompanyOriginator": "Beijing Tiantan Biological Products Co Ltd", "AddedDate": "2014-01-08T00:00:00Z", "@name": "measles/mumps/rubella/varicella vaccine (live-attenuated), Beijing Tiantan Biological Products", "Summary": "Beijing Tiantan Biological Products is investigating a live-attenuated combined vaccine for the potential prevention of <b>measles</b>, mumps, rubella and varicella. In November 2013, a clinical trial application was filed in China [1495541], [1511680].In November 2013, the company intended to develop this vaccine as a class 7 preventive biologic in China [1495541].", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "Beijing Tiantan Biological Products Co Ltd"}, "Technologies": {"Technology": ["Biological therapeutic", "Virus recombinant"]}, "IndicationsPrimary": {"Indication": ["Measles virus infection", "Mumps virus infection", "Rubella virus infection", "Varicella zoster virus infection"]}, "@id": "89450", "@lastModificationDate": "2014-01-08T00:00:00Z", "ActionsSecondary": {"Action": ["Live attenuated viral vaccine", "Prophylactic vaccine"]}}, {"CompanyOriginator": "Guizhou Taibang Biological Products Co Ltd", "AddedDate": "2013-09-20T00:00:00Z", "@name": "human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guizhou Taibang Biological Products", "Summary": "Guizhou Taibang Biological Products (formerly Guiyang Qianfeng Biological Products) has developed and launched an intramuscular plasma-derived human immunoglobulin for the prevention of <b>measles</b> and infectious hepatitis. It was assumed that launch took place in China shortly after its approval there in 2000 [1474650], [1477604].", "@phaseHighest": "Launched", "CompaniesPrimary": {"Company": "Guizhou Taibang Biological Products Co Ltd"}, "Technologies": {"Technology": ["Antibody polyclonal", "Biological therapeutic", "Blood constituents", "Immunoglobulin", "Intramuscular formulation", "Solution"]}, "IndicationsPrimary": {"Indication": ["Hepatitis virus infection", "Measles virus infection"]}, "@id": "87540", "@lastModificationDate": "2013-09-24T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Immunostimulant", "Unspecified drug target"]}}, {"CompanyOriginator": "Wuhan Institute of Biological Products Co Ltd", "AddedDate": "2013-09-04T00:00:00Z", "@name": "measles/Japanese encephalitis vaccine (live attenuated), Wuhan Institute of Biological Products", "Summary": "Wuhan Institute of Biological Products is investigating a combined live attenuated vaccine for the potential prevention for <b>measles</b> and Japanese encephalitis virus infection. In February 2012, an application for clinical trials was submitted to China SFDA. In November 2012, the application was rejected [1473364], [1473367].", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "Wuhan Institute of Biological Products Co Ltd"}, "Technologies": {"Technology": ["Biological therapeutic", "Parenteral formulation unspecified"]}, "IndicationsPrimary": {"Indication": ["Japanese encephalitis virus infection", "Measles virus infection"]}, "@id": "87292", "@lastModificationDate": "2013-09-04T00:00:00Z", "ActionsSecondary": {"Action": ["Live attenuated viral vaccine", "Prophylactic vaccine"]}}, {"CompanyOriginator": "Dalian Aleph Biomedical Co Ltd", "AddedDate": "2013-06-14T00:00:00Z", "@name": "measles/mumps/rubella vaccine, Dalian Aleph Biomedical", "Summary": "Dalian Aleph Biomedical is investigating a triple vaccine, for the potential prevention of <b>measles</b>, mumps, and rubella. In June 2013, the vaccine was listed as being under development on the company's website pipeline [1438975].", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "Dalian Aleph Biomedical Co Ltd"}, "Technologies": {"Technology": ["Biological therapeutic", "Parenteral formulation unspecified"]}, "IndicationsPrimary": {"Indication": ["Measles virus infection", "Mumps virus infection", "Rubella virus infection"]}, "@id": "85750", "@lastModificationDate": "2013-06-14T00:00:00Z", "ActionsSecondary": {"Action": "Prophylactic vaccine"}}, {"CompanyOriginator": "Banghe Pharmaceutical Co Ltd", "AddedDate": "2013-05-23T00:00:00Z", "@name": "human immunoglobulin (intramuscular, measles/hepatitis virus infection), Banghe Pharmaceutical", "Summary": "Banghe Pharmaceutical has developed and launched an intramuscular plasma-derived human immunoglobulin for the prevention of <b>measles</b> and infectious hepatitis, and for use in combination with antibiotics for the treatment of severe bacterial or viral infections. It was assumed that launch took place in China shortly after its approval there in 2002 [1424541], [1424500].", "@phaseHighest": "Launched", "CompaniesPrimary": {"Company": "Banghe Pharmaceutical Co Ltd"}, "Technologies": {"Technology": ["Antibody polyclonal", "Biological therapeutic", "Blood constituents", "Immunoglobulin", "Intramuscular formulation", "Solution"]}, "IndicationsPrimary": {"Indication": ["Hepatitis virus infection", "Measles virus infection"]}, "@id": "85214", "@lastModificationDate": "2013-09-24T00:00:00Z", "ActionsSecondary": {"Action": ["Anti-inflammatory", "Antiviral", "Immunostimulant", "Unspecified drug target"]}}, {"CompanyOriginator": "Guangdong Weilun Biological Products Co Ltd", "AddedDate": "2013-04-29T00:00:00Z", "@name": "human immunoglobulin (intramuscular, measles/hepatitis virus infection), Guangdong Weilun Biological Products", "Summary": "Guangdong Weilun Biological Products has developed and launched an intramuscular plasma-derived human immunoglobulin for the prevention of <b>measles</b> and infectious hepatitis, and for use in combination with antibiotics for the treatment of severe bacterial or viral infections. It was assumed that launch took place in China shortly after its approval there in 2000 [1411223], [1411222].", "@phaseHighest": "Launched", "CompaniesPrimary": {"Company": "Guangdong Weilun Biological Products Co Ltd"}, "Technologies": {"Technology": ["Antibody polyclonal", "Biological therapeutic", "Blood constituents", "Immunoglobulin", "Intramuscular formulation", "Solution"]}, "IndicationsPrimary": {"Indication": ["Hepatitis virus infection", "Measles virus infection"]}, "@id": "84826", "@lastModificationDate": "2013-09-24T00:00:00Z", "ActionsSecondary": {"Action": ["Anti-inflammatory", "Antiviral", "Immunostimulant", "Unspecified drug target"]}}, {"CompanyOriginator": "Shenzhen Weiwu Guangming Biological Products Co Ltd", "AddedDate": "2013-04-29T00:00:00Z", "@name": "human immunoglobulin (intramuscular, measles/hepatitis virus infection), Shenzhen Weiwu Guangming Biological Products", "Summary": "Shenzhen Weiwu Guangming Biological Products has developed and launched an intramuscular plasma-derived human immunoglobulin for the prevention of <b>measles</b> and infectious hepatitis, and for use in combination with antibiotics for the treatment of severe bacterial or viral infections. It was assumed that launch took place in China shortly after its approval there in 1999 [1410664], [1409381].", "@phaseHighest": "Launched", "CompaniesPrimary": {"Company": "Shenzhen Weiwu Guangming Biological Products Co Ltd"}, "Technologies": {"Technology": ["Antibody polyclonal", "Biological therapeutic", "Blood constituents", "Immunoglobulin", "Intramuscular formulation", "Solution"]}, "IndicationsPrimary": {"Indication": ["Hepatitis virus infection", "Measles virus infection"]}, "@id": "84800", "@lastModificationDate": "2013-09-24T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Immunostimulant", "Unspecified drug target"]}}, {"CompanyOriginator": "Sichuan Yuanda Shuyang Pharmaceutical Co Ltd", "AddedDate": "2013-04-22T00:00:00Z", "@name": "human immunoglobulin (intramuscular, measles/hepatitis virus infection), Sichuan Yuanda Shuyang Pharmaceutical", "Summary": "Sichuan Yuanda Shuyang Pharmaceutical has developed and launched an intramuscular plasma-derived human immunoglobulin for the prevention of <b>measles</b> and hepatitis virus infection. It was assumed that launch took place in China shortly after its approval there in 1998 [1405799], [1407050].", "@phaseHighest": "Launched", "CompaniesPrimary": {"Company": "Sichuan Yuanda Shuyang Pharmaceutical Co Ltd"}, "Technologies": {"Technology": ["Antibody polyclonal", "Biological therapeutic", "Blood constituents", "Immunoglobulin", "Intramuscular formulation", "Solution"]}, "IndicationsPrimary": {"Indication": ["Hepatitis virus infection", "Measles virus infection"]}, "@id": "84689", "@lastModificationDate": "2013-09-24T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Immunomodulator", "Unspecified drug target"]}}, {"CompanyOriginator": "Sevapharma Inc", "AddedDate": "2013-03-11T00:00:00Z", "@name": "Trivivac", "Summary": "Sevapharma is developing Trivivac for the potential prevention of <b>measles</b>, mumps and rubella (MMR). In September 2012, a phase II/III trial was initiated in Thailand. In April 2014, the trial was ongoing [1382434].In September 2012, an open-label, single-group-assignment, phase II/III trial (NCT01763268; Trivivac2012) was initiated in healthy infants aged 9 to 14 months (n = 200). At that time, the study was expected to be completed in August 2015 [1382434].", "@phaseHighest": "Phase 3 Clinical", "CompaniesPrimary": {"Company": "Sevapharma Inc"}, "Technologies": {"Technology": ["Biological therapeutic", "Subcutaneous formulation"]}, "IndicationsPrimary": {"Indication": ["Measles virus infection", "Mumps virus infection", "Rubella virus infection"]}, "@id": "83793", "@lastModificationDate": "2013-03-12T00:00:00Z", "ActionsSecondary": {"Action": ["Live attenuated viral vaccine", "Prophylactic vaccine"]}}, {"CompanyOriginator": "Chengdu Institute of Biological Products", "AddedDate": "2013-03-01T00:00:00Z", "@name": "measles/Japanese encephalitis conjugate attenuated vaccine, Chengdu Institute of Biological Products", "Summary": "Chengdu Institute of Biological Products is investigating a live attenuated <b>measles</b> and Japanese encephalitis conjugate vaccine for the potential prevention for <b>measles</b> and JEV infection. In November 2011, an IND application of the drug was accepted by the SFDA; in November 2012, the application was rejected [1384044], [1385139].", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "Chengdu Institute of Biological Products"}, "Technologies": {"Technology": ["Biological therapeutic", "Parenteral formulation unspecified"]}, "IndicationsPrimary": {"Indication": ["Japanese encephalitis virus infection", "Measles virus infection"]}, "@id": "83455", "@lastModificationDate": "2013-03-01T00:00:00Z", "ActionsSecondary": {"Action": ["Live attenuated viral vaccine", "Prophylactic vaccine"]}}, {"CompanyOriginator": "Hebei Da'an Pharmaceutical Co Ltd", "AddedDate": "2013-01-14T00:00:00Z", "@name": "human immunoglobulin (intramuscular, measles/hepatitis virus infection), Hebei Da'an Pharmaceutical", "Summary": "Hebei Da'an Pharmaceutical has developed and launched an intramuscular plasma-derived human immunoglobulin for the prevention of <b>measles</b> and hepatitis virus infection. In 2006, the product was approved by the SFDA and was assumed to be launched in China shortly after. However, by August 2012, the company had stopped manufacturing this product because of a modification to the manufacturing...", "@phaseHighest": "Registered", "CompaniesPrimary": {"Company": "Hebei Da'an Pharmaceutical Co Ltd"}, "Technologies": {"Technology": ["Antibody polyclonal", "Biological therapeutic", "Blood constituents", "Immunoglobulin", "Intramuscular formulation"]}, "IndicationsPrimary": {"Indication": ["Hepatitis virus infection", "Measles virus infection"]}, "@id": "82763", "@lastModificationDate": "2013-11-05T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Immunomodulator", "Unspecified drug target"]}}, {"CompanyOriginator": "Beijing Minhai Biotechnology Co Ltd", "AddedDate": "2012-11-27T00:00:00Z", "@name": "measles/rubella vaccine (subcutaneous, live), Beijing Minhai Biotechnology", "Summary": "Beijing Minhai Biotechnology has developed a combination vaccine consisting of live <b>measles</b> and rubella viruses, for the sc prevention of <b>measles</b> and rubella virus infections. In November 2011, an NDA was filed with the SFDA; in October 2012, the vaccine was approved in China [1337701], [1343776].", "@phaseHighest": "Registered", "CompaniesPrimary": {"Company": "Beijing Minhai Biotechnology Co Ltd"}, "Technologies": {"Technology": ["Biological therapeutic", "Subcutaneous formulation"]}, "IndicationsPrimary": {"Indication": ["Measles virus infection", "Rubella virus infection"]}, "@id": "82024", "@lastModificationDate": "2012-11-27T00:00:00Z", "ActionsSecondary": {"Action": ["Live attenuated viral vaccine", "Prophylactic vaccine"]}}, {"CompanyOriginator": "Shanxi Kangbao Biological Products Co Ltd", "AddedDate": "2012-11-02T00:00:00Z", "@name": "human immunoglobulin (im, hepatitis, measles), Shanxi Kangbao Biological Products", "Summary": "Shanxi Kangbao Biological Products has developed and launched an intramuscular plasma-derived human immunoglobulin for the prevention of hepatitis and <b>measles</b>. It can be used as an adjunct to antibiotics to increase efficacy against serious infections caused by bacteria or virus. The product was assumed to be launched in China shortly after its approval there in 1998 [1336339], [1336363].", "@phaseHighest": "Launched", "CompaniesPrimary": {"Company": "Shanxi Kangbao Biological Products Co Ltd"}, "Technologies": {"Technology": ["Antibody polyclonal", "Biological therapeutic", "Blood constituents", "Immunoglobulin", "Intramuscular formulation"]}, "IndicationsPrimary": {"Indication": ["Hepatitis virus infection", "Measles virus infection"]}, "@id": "81711", "@lastModificationDate": "2013-09-24T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Immunostimulant", "Unspecified drug target"]}}, {"CompanyOriginator": "BioNet-Asia Co Ltd", "AddedDate": "2012-10-01T00:00:00Z", "@name": "measles vaccine, BioNet-Asia", "Summary": "BioNet-Asia, under license from an unspecified manufacturer, has launched an sc vaccine for the prevention of <b>measles</b>. By August 2011, the vaccine was available in Thailand [1218321].", "@phaseHighest": "Launched", "CompaniesPrimary": {"Company": "BioNet-Asia Co Ltd"}, "Technologies": {"Technology": ["Biological therapeutic", "Subcutaneous formulation"]}, "IndicationsPrimary": {"Indication": "Measles virus infection"}, "@id": "81219", "@lastModificationDate": "2012-10-02T00:00:00Z", "ActionsSecondary": {"Action": "Prophylactic vaccine"}}]}, "@hits": "20", "@totalResults": "133", "@offset": "0"}}